Background: High-dose testosterone treatment is a well-known, though still controversial, therapy in boys with tall stature. Methods: 161 boys with constitutional tall stature were treated at two different treatment centers (center A 114 patients; center B 47 patients). In center A, boys were treated with 500 mg and in center B with 250 mg testosterone enanthate intramuscularly every 2 weeks. Predicted adult height (PAH) was calculated according to the Bayley/Pinneau method using the Greulich-Pyle method for bone age determination. Results: At onset of treatment, the patients at the two centers did not differ with respect to chronological age (center A 14.2 ± 1.3 years; center B 13.5 ± 1.1 years), height (center A 187.8 ± 7.3 cm; center B 185.5 ± 5.5 cm), bone age (center A 13.8 ± 0.8 years; center B 13.6 ± 0.7 years), or PAH (center A 205.2 ± 5.2 cm; center B 204.8 ± 5.5 cm). Mean treatment duration was significantly longer in center A than in center B (14.2 ± 4.0 vs. 11.3 ± 2.2 months). At the end of the testosterone treatment, PAH did not differ significantly (center A 197.7 ± 5.3 cm; center B 196.1 ± 4.7 cm). The mean reduction in PAH at the end of treatment was 7.6 ± 5.0 cm (center A) and 8.7 ± 5.6 cm (center B) which is ∼50% of the expected growth at onset of treatment. Conclusions: A testosterone enanthate dose of 250 mg every 2 weeks was as effective in reducing adult height in boys with tall stature as a dose of 500 mg every 2 weeks.

1.
De Waal WJ, Greyn-Fokker MH, Stijnen T, et al: Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children. J Clin Endocrinol Metab 1996;81:1206–1216.
2.
Binder G, Grauer ML, Wehner AV, Wehner F, Ranke MB: Outcome in tall stature. Final height and psychological aspects in 220 patients with and without treatment. Eur J Pediatr 1997;156:905–910.
3.
Drop SL, Greggio N, Cappa M, Bernasconi S: Current concepts in tall stature and overgrowth syndromes. J Pediatr Endocrinol Metab 2001;14(suppl 2):975–984.
4.
Noordam C, Van DS, Otten BJ: Treatment of tall stature in boys with somatostatin analogue 201–995: effect on final height. Eur J Endocrinol 2006;154:253–257.
5.
Thomsett MJ: Referrals for tall stature in children: a 25-year personal experience. J Paediatr Child Health 2009;45:58–63.
6.
Rozendaal L, Le CS, Wit JM, Hennekam RC, The Dutch Marfan Working Group: Growth-reductive therapy in children with marfan syndrome. J Pediatr 2005;147:674–679.
7.
De Waal WJ, de Muinck-Keiser-Schrama S, Drop SL: Hormonal therapy of constitutionally tall children (in Dutch). Ned Tijdschr Geneeskd 1998;142:693–697.
8.
Rooman RP, De Beeck LO, Martin M, Van Doorn J, Mohan S, Du Caju MV: Ethinylestradiol and testosterone have divergent effects on circulating IGF system components in adolescents with constitutional tall stature. Eur J Endocrinol 2005;152:597–604.
9.
Bramswig JH, Von Lengerke HJ, Schmidt H, Schellong G: The results of short-term (6 months) high-dose testosterone treatment on bone age and adult height in boys of excessively tall stature. Eur J Pediatr 1988;148:104–106.
10.
Bettendorf M, Heinrich UE, Schonberg DK, Grulich-Henn J: Short-term, high-dose testosterone treatment fails to reduce adult height in boys with constitutional tall stature. Eur J Pediatr 1997;156:911–915.
11.
Greulich W, Pyle S: Radiographic Atlas of Skeletal Development of the Hand and Wrist. Stanford, Stanford University Press, 1959.
12.
Bayley N, Pinneau SR: Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423–441.
13.
Bramswig J: Diagnostik und Therapie des Hochwuchses. Monatsschr Kinderheilkd 2004;152:509–516.
14.
Hartmann AA, Burg G: Fulminant acne in Klinefelter syndrome treated with testosterone. A side effect of anti-tallness therapy (in German). Monatsschr Kinderheilkd 1989;137:466–467.
15.
Traupe H, Von Muhlendahl KE, Bramswig J, Happle R: Acne of the fulminans type following testosterone therapy in three excessively tall boys. Arch Dermatol 1988;124:414–417.
16.
Bramswig JH, Nieschlag E, Schellong G: Pituitary-gonadal function in boys after high dose testosterone treatment for excessively tall stature. Acta Endocrinol (Copenh) 1984;107:97–103.
17.
Hendriks AE, Boellaard WP, Van Casteren NJ, et al: Fatherhood in tall men treated with high-dose sex steroids during adolescence. J Clin Endocrinol Metab 2010;95:5233–5240.
18.
Lemcke B, Zentgraf J, Behre HM, Kliesch S, Bramswig JH, Nieschlag E: Long-term effects on testicular function of high-dose testosterone treatment for excessively tall stature. J Clin Endocrinol Metab 1996;81:296–301.
19.
De Waal WJ, Vreeburg JT, Bekkering F, et al: High dose testosterone therapy for reduction of final height in constitutionally tall boys: does it influence testicular function in adulthood? Clin Endocrinol (Oxf) 1995;43:87–95.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.